Regulatory Post Marketing Surveillance Study on YAZ

Inclusion Criteria: * Healthy female subjects * requesting contraception * suggesting PMDD by Physician who are also requesting contraception * with acne who are also requesting contraception * Age: 18 - 50 years * Women who is prescribed YAZ first, during study period Exclusion Criteria: * Women who are contraindicated based on the label of YAZ * Presence or a history of venous or arterial thrombotic/ thromboembolic events (e.g. deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident * Presence or history of prodromi of a thrombosis (e.g. transient ischaemic attack, angina pectoris) * History of migraine with focal neurological symptoms * Diabetes mellitus with vascular involvement * The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis may also constitute a contraindication * Pancreatitis or a history thereof if associated with severe hypertriglyceridemia * Presence or history of severe hepatic disease as long as liver function values have not returned to normal * Severe renal insufficiency or acute renal failure * Presence or history of liver tumours (benign or malignant) * Known or suspected sex-steroid influenced malignancies (e.g. of the genital organs or the breasts) * Undiagnosed vaginal bleeding * Known or suspected pregnancy * Hypersensitivity to the active substances or to any of the excipients